NASDAQ$ATRA
Atara Biotherapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Atara Biotherapeutics reported financial results and operational progress for Q1 2024.
Atara Biotherapeutics reported a net loss of $31.8 million, or $0.23 per share, for the first quarter 2024, compared to a net loss of $74.8 million, or $0.72 per share, for the same period in 2023. Total revenues were $27.4 million for the first quarter 2024, as compared to $1.2 million for the same period in 2023. The company's cash, cash equivalents, and short-term investments totaled $46.2 million as of March 31, 2024.
- Atara is on track to submit the Tab-cel BLA in Q2 2024.
- Phase 1 study of ATA3219 in Lupus Nephritis is expected to begin in Q4 2024.
- Enrollment of ATA3219 Non-Hodgkin’s Lymphoma study has been initiated, with initial clinical data expected in Q4 2024.
- Atara's cash runway is expected to last into 2027.
Headline financials
Revenue & EPS history
Atara · Revenue · Quarterly
$27.4M
Forward guidance
Atara expects full year 2024 operating expenses to decrease by approximately 35% from 2023 and anticipates funding operations into 2027.
Tailwinds
- Anticipated payments of $20 million and $60 million from Pierre Fabre contingent upon the successful acceptance and approval of the tab-cel BLA, respectively
- Anticipated purchases of tab-cel inventory through the manufacturing transfer date by Pierre Fabre
- Anticipated reimbursement for tab-cel global development costs through the BLA transfer by Pierre Fabre
- Operating efficiencies resulting from completed workforce reductions
- Anticipated royalties from sales of tab-cel by Pierre Fabre in the U.S. post BLA approval
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
-2.0%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-2.1%
Avg return
30 days after
37%
17 / 46 earnings
Positive
+36.3%
Q2 2022
Best reaction
-24.2%
Q1 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +11.5% | +9.6% | +17.2% | |
| Q4 2025 | -0.6% | -16.4% | -10.7% | |
| Q3 2025 | -1.3% | +4.3% | +43.3% | |
| Q1 2025 | +4.8% | +6.8% | +6.3% | |
| Q4 2024 | +3.9% | -9.2% | +10.6% | |
| Q3 2024 | +21.2% | +2.0% | -7.0% | |
| Q2 2024 | +5.8% | -7.5% | +9.6% | |
| Q1 2024 | -6.3% | +6.9% | -6.5% | |
| Q4 2023 | +3.6% | +4.0% | -1.4% | |
| Q3 2023 | -7.8% | +2.3% | -49.8% | |
| Q2 2023 | -16.4% | -7.1% | -31.6% | |
| Q1 2023 | -16.2% | -26.5% | -43.3% | |
| Q4 2022 | -12.6% | -18.7% | -48.2% | |
| Q3 2022 | -18.0% | +8.5% | +0.2% | |
| Q2 2022 | +36.3% | +69.8% | +32.3% | |
| Q1 2022 | -5.3% | -22.2% | -29.7% | |
| Q4 2021 | -22.6% | -32.9% | -30.4% | |
| Q3 2021 | -3.1% | -4.4% | -8.9% | |
| Q2 2021 | +0.8% | -1.5% | +17.9% | |
| Q1 2021 | -3.9% | -3.3% | -5.1% | |
| Q4 2020 | +1.0% | -4.2% | -14.4% | |
| Q3 2020 | -5.9% | +9.0% | +72.0% | |
| Q2 2020 | +1.9% | +3.5% | +4.8% | |
| Q1 2020 | +4.9% | +17.5% | +11.7% | |
| Q4 2019 | +8.8% | +11.5% | -24.4% | |
| Q3 2019 | +10.2% | +6.9% | +15.0% | |
| Q2 2019 | +10.6% | +17.3% | +16.4% | |
| Q1 2019 | -24.2% | -27.1% | -35.6% | |
| Q4 2018 | -13.3% | -8.5% | -7.4% | |
| Q3 2018 | -1.9% | -3.5% | +5.7% | |
| Q2 2018 | -2.1% | +0.5% | +9.1% | |
| Q1 2018 | -5.8% | +1.7% | +0.6% | |
| Q4 2017 | -10.6% | -8.6% | -9.5% | |
| Q3 2017 | -6.3% | -4.9% | +3.1% | |
| Q2 2017 | -3.3% | -3.6% | -1.3% | |
| Q1 2017 | -5.1% | -7.0% | -10.2% | |
| Q4 2016 | +21.4% | +16.8% | -1.2% | |
| Q3 2016 | +17.2% | +45.6% | +32.6% | |
| Q2 2016 | -9.5% | -14.7% | -14.3% | |
| Q1 2016 | -5.5% | — | — | |
| Q4 2015 | -18.5% | — | — | |
| Q3 2015 | +4.7% | — | — | |
| Q2 2015 | -11.4% | — | — | |
| Q1 2015 | -1.7% | — | — | |
| Q4 2014 | -5.9% | — | — | |
| Q3 2014 | -15.5% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro